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Abstract
Background: Mycobacterium tuberculosis (MTB) is a major cause of morbidity and mortality in the
world. To combat against this pathogen, immune cells release cytokines including tumor necrosis
factor-α (TNF-α), which is pivotal in the development of protective granulomas. Our previous
results showed that Bacillus Calmette Guerin (BCG), a mycobacterium used as a model to
investigate the immune response against MTB, stimulates the induction of TNF-α via mitogen-
activated protein kinase (MAPK) in human blood monocytes. Since MAPK phosphatase-1 (MKP-1)
is known to regulate MAPK activities, we examined whether MKP-1 plays a role in BCG-induced
MAPK activation and cytokine expression.
Results:  Primary human blood monocytes were treated with BCG and assayed for MKP-1
expression. Our results demonstrated that following exposure to BCG, there was an increase in
the expression of MKP-1. Additionally, the induction of MKP-1 was regulated by p38 MAPK and
extracellular signal-regulated kinase 1 and 2 (ERK1/2). Surprisingly, when MKP-1 expression was
blocked by its specific siRNA, there was a significant decrease in the levels of phospho-MAPK (p38
MAPK and ERK1/2) and TNF-α inducible by BCG.
Conclusions: Since TNF-α is pivotal in granuloma formation, the results indicated an unexpected
positive function of MKP-1 against mycobacterial infection as opposed to its usual phosphatase
activity.
Background
Tuberculosis (TB) remains a major cause of morbidity and
mortality in the world, especially in the developing coun-
tries [1]. The disease is caused by Mycobacterium tuberculo-
sis  (MTB) and approximately one third of the world's
population has been infected by this pathogen. In a recent
report, World Health Organization (WHO) estimated that
there are 9.2 million new TB cases around the world in
2006 [1].
In response to MTB infection, induction of cytokines by
immune cells is an important defense mechanism. The
infected macrophages secrete intercellular signaling fac-
tors, proinflammatory cytokines, to mediate the inflam-
matory response leading to the formation of granuloma
and induction of T-cell mediated immunity [2]. In order
to understand TB pathogenesis, signaling pathways
induced by mycobacteria have long been a subject of
interest. Mitogen activated protein kinases (MAPKs)
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including extracellular signal-regulated kinase 1 and 2
(ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK)
have been implicated as important cellular signaling mol-
ecules activated by mycobacteria [3]. Previous reports
have shown that p38 MAPK and ERK1/2 are required in
the induction of TNF-α expression in human monocytes
infected with M. tuberculosis H37Rv [4]. We have further
revealed the significant role of MAPKs in the signal trans-
duction events of mycobacterial activation of primary
human blood monocytes (PBMo) leading to cytokine
expressions via the interaction with PKR [5]. However, the
subsequent events as to how MAPK is regulated and how
such regulation affects cytokine production in response to
mycobacteria remain to be elucidated.
Since MAPKs are activated by phosphorylation, dephos-
phorylation of MAPKs seems to be an efficient process to
inactivate their activities. It can be achieved by specific
protein kinase phosphatases which can remove the phos-
phate group from MAPKs. Examples of these phos-
phatases include tyrosine phosphatases, serine/threonine
phosphatases, and dual-specificity phosphatases
(DUSPs). Some DUSPs are also known as MAPK phos-
phatases (MKPs) [6-8]. Currently, there are at least 10
MKPs identified, while MKP-1 is the most studied mem-
ber of the family. The regulatory role of MKP-1 on
cytokine induction is best demonstrated by MKP-1 knock-
out (KO) macrophages in response to lipopolysaccharide
(LPS), a cell wall component of Gram-negative bacteria.
MKP-1 KO macrophages showed prolonged phosphoryla-
tion of p38 MAPK and JNK as well as increased produc-
tion of TNF-α in response to LPS treatment [9]. Consistent
with these results, another group further revealed that
LPS-treated MKP-1 KO bone marrow-derived macro-
phages show increased AP-1 DNA-binding activity [10].
Also, they showed that LPS-induced MKP-1 expression is
dependent on myeloid differentiation factor 88 (MyD88)
and TIR domain-containing adaptor inducing IFN-β
(TRIF) [10], thus demonstrating the role of MKP-1 in sig-
nal transduction.
Not only LPS, other TLR inducers including CpG, pepti-
doglycan, poly IC, and Pam3Cys can regulate cytokine
expressions including TNF-α, IL-10 via MKP-1 activities
[10,11]. In these processes, MKP-1 serves to mitigate the
undesirable effects of septic shock and maintain organ
functions by restraining the inflammatory responses fol-
lowing bacterial infection. Another example of MKP-1
function is the immune response to Staphylococcus aureus
(S. aureus), a Gram positive bacteria. There are higher lev-
els of cytokine production including TNF-α, IL-6, and
MIP-1α in MKP-1 KO mice infected with S. aureus [12].
Also, the mice would have a rapid development of multi-
organ dysfunction as well as faster mortality rate upon
challenge with heat-killed S. aureus [12]. Taken together,
these results suggest that MKP-1 protects the host from
overactivation of the immune system in response to Gram
negative or Gram positive bacteria.
In the past, it was believed that different MKP/DUSP fam-
ily members have overlapping functions. However, the
emergence of DUSP2 turned the concept up side down
[13]. It was shown that DUSP2 behaves differently and is
opposite to the function as stated above. In DUSP2 KO
cells, they produced less inflammatory mediators, imply-
ing that DUSP2 may play a role in mediating instead of
limiting inflammation. For instances, when DUSP2 KO
macrophages were treated with LPS, there were less TNF,
IL-6, nitric oxide, IL-12-producing cells when compared
to those of the wild type counterparts [13]. When the
DUSP2 KO bone marrow-derived mast cells were first sen-
sitized with immunoglobulin E (IgE) receptor (FcεRI) and
then stimulated with dinitrophenol-heat stable antigen,
they produced lower TNF mRNA levels, diminished IL-6
production, less phosphorylation of ERK1/2, p38 MAPK,
and less transcriptional activities by Elk1 and NFAT-AP-1
[13].
These unexpected positive regulations of immune cell
functions by DUSP2 have been hypothesized to be due to
crosstalks between MAPKs [13]. Stimulation of KO mast
cells and macrophages showed increases in phosphoryla-
tion of JNK. Moreover, inhibition of JNK by small mole-
cule inhibitors showed increases in phosphorylation of
ERK [13]. The authors also showed that there were physi-
cal interactions of DUSP2 with ERK2, DUSP2 with JNK2,
as well as DUSP2 and p38 MAPK after stimulation of the
cells with dinitrophenol-heat stable antigen. Nevertheless,
the details of the crosstalks between MAPKs and phos-
phatases need further investigation. Thus, the MKP family
plays a critical role in the regulation of immune responses.
Innate immune response protects the host from MTB
infection by secretion of cytokines including TNF-α in
immune cells. Meanwhile, MAPK is one of the critical pro-
teins in the regulation of immunity and cytokine expres-
sion. Since MAPK is regulated by MKP-1 in response to
LPS and the activation of MAPK is important in BCG-
induced cytokine expression, we hypothesize that MKP-1
plays a critical role in the immune regulation of BCG in
human monocytes. We examined the involvement of
MKP-1 in BCG-induced MAPK activation and its conse-
quent cytokine expression. Here, we present evidences
that MKP-1 plays an unexpected role in the regulation of
cytokine induction by BCG through its control of MAPK
phosphorylation.
Results
Different inducers show differential induction of MKP-1
It has been reported that many inducers including growth
factors, LPS, peptidoglycan, and dexamethasone can stim-
ulate the expression of MKP-1 in human macrophages,BMC Immunology 2009, 10:64 http://www.biomedcentral.com/1471-2172/10/64
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microglia, mast cells or fibroblasts [6]. To investigate the
role of different TLR inducers in MKP-1 induction process
in human blood monocytes, the level of MKP-1 mRNA
was measured by quantitative polymerase chain reaction
(QPCR) method. PBMo were isolated from primary
human blood mononuclear cells and stimulated with
Pam3Cys (TLR2 agonist), poly IC (TLR3 agonist), or LPS
(TLR4 agonist) for 1 and 3 hours. Following exposure to
Pam3Cys or LPS, there were significant inductions of
MKP-1 mRNA levels within 1 hour of treatment (Figure
1A). These effects on MKP-1 induction continued for 3
hours post-treatment with Pam3Cys (Figure 1A). In con-
trast, poly IC did not induce MKP-1 (Figure 1A). The
results indicate that different inducers showed differential
up-regulation of MKP-1 expression.
LPS induces MKP-1 transcription
LPS has been extensively used to demonstrate the role of
MKP-1 in immune response both in vivo and  in vitro
[9,12]. To establish a foundation for interpretation of sub-
sequent experimental results, LPS was used as a positive
control for the induction of MKP-1 expression. To deter-
mine the levels of MKP-1 in response to LPS, kinetics of
MKP-1 transcription were determined by QPCR. There
was a significant induction of MKP-1 mRNA, which
peaked as early as 1 hour upon LPS stimulation, and the
levels gradually decreased over a course of 6 hours. These
results showed that LPS induced MKP-1 expression (Fig-
ure 1B).
BCG induces MKP-1 expression
Next, to demonstrate the induction of specific phos-
phatases by BCG, kinetics of MKP-1 expression in PBMo
was studied by using QPCR during BCG treatment. Simi-
lar to the results produced by LPS, upon the addition of
BCG (MOI = 1 CFU/cell), there was a significant induc-
tion of MKP-1 mRNA within 1 hour of BCG treatment as
determined by Taqman probe specific for MKP-1 (Figure
2A). The effects lasted for at least 6 hours (Figure 2A).
To examine whether the changes of protein production
were in parallel to that of the mRNA levels, the protein
levels of MKP-1 were measured by Western blotting. In
response to BCG, PBMo produced the MKP-1 protein as
early as 30 minutes after treatment. The protein levels
were maintained for 2 hours and dropped to basal levels
at 3 hours (Figure 2B). The results demonstrated that there
was MKP-1 induction in response to BCG activation in
human monocytes.
BCG-induced MKP-1 expression is dependent on p38 
MAPK and ERK1/2
It has been shown that inhibition of p38 MAPK either by
specific inhibitor or siRNA reduced the expression of
MKP-1 in LPS- or peptidoglycan-treated macrophages
[14]. To determine the mechanisms involved in the BCG-
induced MKP-1 expression, PBMo were pretreated with
several inhibitors including PD98059 (inhibitor for MAP
kinase kinase [MEK] or ERK1/2), SB203580 (inhibitor for
p38 MAPK), SP600125 (inhibitor for JNK), and CAPE
(inhibitor for NF-κB) for 1 hour. A range of concentra-
tions of each inhibitor was used to test their optimal con-
centrations and effects on cell viability and kinase
inhibitions. BCG was added afterwards and total RNA was
harvested. The results demonstrated that, with the inhibi-
tion of ERK1/2 and p38 MAPK activities by their corre-
sponding relatively specific inhibitors, MKP-1 expressions
were significantly reduced (Figure 3). In addition, using
higher dose of SB203580, we showed that the inhibition
is increased further (data not shown). On the contrary,
pretreatment of the cells with CAPE and SP600125 did
not affect the induction of MKP-1 by BCG (Figure 3).
These results suggest that BCG-induced MKP-1 expression
is dependent on both p38 MAPK and ERK1/2.
Different inducers show differential induction of MKP-1 Figure 1
Different inducers show differential induction of 
MKP-1. (A) Primary human blood monocytes were stimu-
lated with LPS (50 ng/ml), Pam3Cys (50 ng/ml), or Poly IC 
(100 μg/ml) for 1 (open bars) and 3 (black bars) hours. Phos-
phate buffered saline (PBS) was used as a reagent control. 
RNA was harvested and MKP-1 mRNA was measured by 
QPCR method. (B) Primary human monocytes were treated 
with LPS (50 ng/ml) for the indicated time points and RNA 
samples were harvested. MKP-1 levels were studied by using 
QPCR. Independent experiments were done on blood cells 
from 4 different donors, and the results are shown as mean ± 
SD. * = p < 0.05.
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Transfection of MKP-1 siRNA into PBMo can reduce BCG-
induced MKP-1 production
Throughout the above experiments, the primary goal was
to examine the induction of MKP-1 by BCG in human
monocytes. Thus, to further examine the role of MKP-1 in
BCG-induced signaling, transfection of siRNA into PBMo
was used to knockdown the activity of MKP-1. To demon-
strate that the MKP-1 siRNA can indeed knockdown the
target gene, PBMo were first transfected with control or
MKP-1 siRNA and then treated with BCG for 3 hours. Lev-
els of MKP-1 mRNA were measured by RT-PCR method.
In Figure 4A, BCG stimulated MKP-1 expression (lanes 1
and 2). In MKP-1 siRNA transfected monocytes, induction
of MKP-1 by BCG was significantly decreased (lanes 2 and
4). The results showed that the siRNA does abrogate the
levels of MKP-1 mRNA.
To further determine whether MKP-1 siRNA affects BCG-
induced MKP-1 at protein levels, PBMo were treated as
above and MKP-1 proteins were measured by Western
blotting. The results showed that BCG could induce MKP-
1 proteins as usual for cells transfected with control siRNA
(Figure 4B, lanes 1-3). However, the levels of BCG-
induced MKP-1 protein expression were reduced in cells
transfected with MKP-1 siRNA (Figure 4B, lanes 4-6).
Together, the results suggest that MKP-1 siRNA not only
reduced the MKP-1 mRNA in BCG treatment but also
abrogated the BCG-induced MKP-1 protein.
LPS-induced cytokine expression is increased by MKP-1 
siRNA
As stated in the literature [9], MKP-1 KO mice showed
increased TNF-α production in response to LPS. On the
basis of the above MKP-1 siRNA results, LPS was then
used as a control to demonstrate the effects of this MKP-1
siRNA system.
PBMo were first transfected with control or MKP-1 siRNA
for 24 hours and then stimulated with LPS for the indi-
cated time periods. Likewise, LPS induced MKP-1 within
1 hour treatment and the effects lasted for at least 6 hours
(Figure 4C, lanes 1-4). The use of MKP-1 siRNA can
reduce the levels of MKP-1 mRNA induced by LPS (Figure
4C, lanes 5-8). On the contrary, TNF-α levels were
increased in MKP-1 siRNA transfected monocytes upon
challenge with LPS (Figure 4C, lanes 5-8). The increases in
BCG induces MKP-1 expression Figure 2
BCG induces MKP-1 expression. (A) Human monocytes 
were treated with BCG (MOI = 1 CFU/cell) for the indicated 
time points and RNA was harvested. MKP-1 level was 
assayed by using QPCR. Results are shown as mean ± SD 
from 3 different donors. * = p < 0.05. (B) Cells were treated 
as in (A) for the indicated time points and proteins were col-
lected. MKP-1 protein levels were measured by Western 
blotting. Independent experiments were done on monocytes 
from 3 different donors and one representative set of results 
is shown. The intensities of the protein bands were deter-
mined by using Bio-Rad Quantity One imaging software. The 
intensities of MKP-1 were normalized to the corresponding 
actin. The values in parenthesis are the relative normalized 
intensities compared to those of untreated cells.
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BCG-induced MKP-1 expression is dependent on p38 
MAPK and ERK1/2. Human monocytes were pretreated 
with several inhibitors including PD98059 (20 μM), SB203580 
(100 nM), SP600125 (100 nM), and CAPE (5 μg/ml) for 1 
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the fold induction of (BCG + inhibitor) over the fold induc-
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100% for comparisons. Independent experiments were per-
formed on blood cells from 4 different donors and the 
results are shown as mean ± SD. * = p < 0.05.
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Transfection of MKP-1 siRNA into primary human blood monocytes can increase LPS-induced TNF-α level while decrease  BCG-induced TNF-α expression Figure 4
Transfection of MKP-1 siRNA into primary human blood monocytes can increase LPS-induced TNF-α level 
while decrease BCG-induced TNF-α expression. Cells were first transfected with control (ctrl) or MKP-1 siRNA (MKP-
1 si, 200 nM) for 24 hours and then treated with different inducers as indicated. (A) After transfection, cells were treated with 
Mock (M) or BCG (B, MOI = 1 CFU/cell) for 3 hours. Levels of MKP-1 mRNA were measured by RT-PCR. (B) Monocytes 
were treated as in (A) for the indicated time points and MKP-1 proteins were measured by Western blotting. (C) Cells were 
treated with LPS (50 ng/ml) for the indicated time points. RNA was harvested, and levels of MKP-1 and TNF-α were measured 
by RT-PCR. For both (B) and (C), the intensities of the PCR/protein bands were determined by using Bio-Rad Quantity One 
imaging software. The intensities of bands were normalized to the corresponding control. The values in parenthesis are the rel-
ative normalized intensities compared to those of the control siRNA-transfected cells without other treatment. (D) BCG 
(MOI = 1 CFU/cell) was added for 3 hours. RNA was harvested and levels of TNF-α, IL-6 and IL-10 were measured by QPCR. 
Percentage change was defined as the percentage of the fold induction of (MKP-1 si + BCG) over the fold induction of (ctrl + 
BCG). Results of (ctrl + BCG) were set as 100%. For (A)-(C), independent experiments were done on monocytes from 3 dif-
ferent donors and one representative set of results is shown. For (D), experiments were performed on 4 different donors and 
the results are shown as mean ± SD. * = p < 0.05.
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cytokine expression induced by LPS in MKP-1 siRNA
transfected cells suggest that the siRNA system is effective
in knocking down the MKP-1 expression and MKP-1 acts
as a negative regulator in LPS-induced TNF-α expression.
BCG-induced cytokine expression is decreased by MKP-1 
siRNA
To investigate the effect of MKP-1 siRNA on BCG-induced
cytokine expression, the levels of TNF-α, IL-6 and IL-10
mRNA were measured by QPCR method. PBMo were
transfected with either control or MKP-1 siRNA. Follow-
ing exposure to BCG with control siRNA, there were sig-
nificant inductions of TNF-α, IL-6 and IL-10 mRNA levels
for 3 hours after treatment as previously reported ([5] and
data not shown). Next, the effects of MKP-1 siRNA were
examined on the cytokine expression induced by BCG.
Surprisingly, there was a significant abrogation of BCG-
induced TNF-α expression by MKP-1 siRNA (Figure 4D).
With the knockdown of MKP-1, the level of BCG-induced
TNF-α was only 60% compared to that of the control cells,
while BCG-induced IL-6 and IL-10 were unchanged in
MKP-1 siRNA transfected cells. The results revealed that
MKP-1 plays a role in the induction of TNF-α expression
upon BCG stimulation, which may be different from that
of its conventional functions in which MKP-1 acts as a
negative regulator in LPS-induced signaling pathways [7].
BCG-induced MAPK phosphorylation is decreased by 
MKP-1 siRNA
The unexpected observations in cytokine expression lead
to the investigation on the effects of MKP-1 siRNA on
BCG-induced MAPK activation. MKP-1 was found to have
a preferential substrate binding to p38 MAPK and JNK
than ERK1/2 [7]. The phosphorylation status of MAPKs
was assessed in control or MKP-1 siRNA transfected
PBMo. Western blotting results demonstrated that BCG-
induced both p38 MAPK and ERK1/2 phosphorylation in
15 minutes (data not shown) and peaked at 30 minutes,
and then returned to basal levels in cells treated with the
control siRNA (Figure 5). Similar to the results of cytokine
expression, phosphorylation of both p38 MAPK and
ERK1/2 in response to BCG was decreased in monocytes
transfected with MKP-1 siRNA instead of the expected
increase in phosphorylation (Figure 5). The results suggest
that MKP-1 knockdown would result in reduced MAPK
phosphorylation by BCG, implying that the reduced level
of TNF-α production in BCG stimulated monocytes is due
to reduced phosphorylation of MAPKs by MKP-1 siRNA.
Discussion
This report presented evidences that a novel function of
MKP-1 is uncovered in cytokine regulation in response to
mycobacterial infection. BCG induces MKP-1 as a rapid
response (Figure 2). The induction mechanism of MKP-1
by BCG is dependent on both ERK1/2 and p38 MAPK
(Figure 3). Using siRNA approach, the functions of MKP-
1 can be examined in primary human monocytes. The
results showed that the BCG-induced MAPKs activation as
well as cytokine expression are downstream of MKP-1
(Figures 4D and 5). Thus, MKP-1 is a critical signaling
molecule that is involved in BCG-induced cytokine
expression.
Previous reports have shown that MKP-1 induced by LPS
or peptidoglycan is dependent on p38 MAPK [14].
Accordingly, BCG-induced MKP-1 can be inhibited by
both p38 MAPK and ERK1/2 inhibitors. Interestingly, it
has been shown that degradation of MKP-1 is reduced
after ERK1/2 phosphorylation [15]. It can be hypothe-
sized that BCG-induced MKP-1 proteins can be stabilized
by ERK1/2 and the detailed mechanisms involved require
more exploration. Also, since the inhibition of MKP-1
expression by both inhibitors (for p38 MAPK and ERK1/
2) was not complete, it is believed that other proteins may
be involved in the BCG-induced MKP-1 expression.
On the basis of the literature results on LPS effects (Figure
6), the original expectation for this project is that MKP-1
acts as a negative regulator. LPS-stimulated MKP-1 KO
peritoneal macrophages showed prolonged phosphoryla-
tion of p38 MAPK and JNK as well as increased produc-
tion of TNF-α [9]. In doing so, LPS-induced MKP-1 could
BCG-induced MAPK phosphorylation is decreased by MKP-1  siRNA Figure 5
BCG-induced MAPK phosphorylation is decreased by 
MKP-1 siRNA. Transfection was done as in Figure 4, and 
BCG (MOI = 1 CFU/cell) was added for the indicated time 
points. Protein samples were harvested and levels of phos-
pho-p38 MAPK (p-p38), phospho-ERK1/2 (p-ERK1/2) and 
actin were measured by Western blotting. Independent 
experiments were done on monocytes from 4 different 
donors and one representative set of results is shown. The 
intensities of the protein bands were determined by using 
Bio-Rad Quantity One imaging software. The intensities of 
phospho-proteins were normalized to the corresponding 
actin. The values in parenthesis are the relative normalized 
intensities compared to those of control siRNA-transfected 
cells without other treatment.
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prevent prolonged TNF-α production as in sepsis which
may lead to severe damage to the host. It was expected
that BCG induces MKP-1 and its induction would corre-
late with the dephosphorylation of MAPKs including p38
MAPK. By blocking the MKP-1 using siRNA, it was
expected to have increased p38 MAPK phosphorylation
and prolonged TNF-α production in response to BCG.
Nevertheless, our results shown here are diametrically
opposite. One possibility for the unexpected results may
be due to non-specific effects of transfection or siRNA.
However, this was not the case since there was a pro-
longed and increased TNF-α expression after the MKP-1
siRNA-transfected monocytes were treated with LPS (Fig-
ure 4C).
There is now a new hypothesis to explain such paradoxical
effects of MKP-1 in TNF-α regulation in which the phos-
phatase plays a role in positive regulation of TNF-α pro-
duction in response to BCG as in the case of DUSP2 [13].
The structures of MKP-1 and DUSP2 are similar, with
which they both contain a MAPK-interacting domain and
a phosphatase catalytic site. By contrast, other DUSP may
have extra domains, e.g., PEST [6]. Here, we postulate that
the function of MKP-1 in BCG-induced signaling is simi-
lar to that of the DUSP2/PAC1.
Actually, the discovery of DUSP2 has initially created
some paradoxical questions. As described, DUSP2
behaves differently from other MKP family members [13].
In DUSP2 KO macrophages treated with LPS, they pro-
duced less inflammatory mediators including less TNF, IL-
6, nitric oxide, and IL-12-producing cells, when compared
to that of the wild type counterparts [13]. Indeed, the
results of these published studies on DUSP2 studies are
quite similar to that of our reported results here.
It is plausible that these unexpected positive regulations
of immune cell functions by DUSP2 were due to cross-
talks between MAPKs [13]. It was shown that there are
interactions between JNK and ERK1/2 pathways [16].
Here, we showed that the sustained activation of JNK
blocks ERK activation (Figure 6). In the DUSP2 situation,
stimulation of KO mast cells and macrophages shows
increased phosphorylation of JNK, and inhibition of JNK
by its own specific inhibitor restores phosphorylation of
ERK1/2 [13].
In the BCG-MKP-1 situation, there is an early phosphor-
ylation of p38 MAPK and ERK1/2. Therefore, it is possible
that JNK may play a role in the crosstalk interaction of
MAPK. However, our preliminary data suggest that the
level of phosphorylated JNK was not increased in PBMo
MKP-1 plays a critical role in the regulation of cytokine expression upon mycobacterial infection Figure 6
MKP-1 plays a critical role in the regulation of cytokine expression upon mycobacterial infection. LPS model was 
provided according to literature findings (Left). In this scenario, LPS activates MKP-1, which in turn dephosphorylates and deac-
tivates phospho-p38 MAPK, resulting in less TNF-α induction. However, the situation in DHP-HSA activation of DUSP2 is 
more complicated (Middle), since the phosphatase activity causes subsequent inhibition of phospho-JNK which leads to the de-
repression of phospho-p38 MAPK. Consequently, the combined effects of this cascade results in more TNF-α expression. The 
unexpected antimycobacterial role of MKP-1 (Right) may be explained by events similar to the DUSP2 effects. In this case 
(Right), there was an inhibition of unknown pathways or kinases downstream of MKP-1, and the unknown factor in turn inhib-
its MAPKs activation leading to more TNF-α induction. The details and kinase targets are yet to be identified.
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transfected with MKP-1 siRNA (data not shown). Thus,
the details of the crosstalk between MAPKs need further
investigation. Here, we present a model to summarize the
results and to hypothesize the existence of an as yet uni-
dentified intermediary factor or factors in the pathways
downstream of MKP-1 effects in the BCG-induced signal-
ing cascade. The unexpected antimycobacterial role of
MKP-1 (Figure 6) may be explained by events similar to
the DUSP2 effects. In this case, BCG induces MKP-1
expression while also activates MAPKs including p38
MAPK and ERK1/2. Downstream of MKP-1, there is an
inhibition of unknown pathways or kinases. The
unknown factor in turn inhibits MAPKs activation, which
ultimately leads to more TNF-α induction (Figure 6).
Conclusions
In summary, MKP-1 plays a critical role in the regulation
of cytokine expression upon mycobacterial infection.
Inhibition of unknown pathways or kinases downstream
of MKP-1, which in turn inhibits MAPKs activation, may
be used to explain the novel function of MKP-1 in enhanc-
ing MAPK activity and consequent TNF-α expression fol-
lowing BCG treatment (Figure 6). Taken together, the role
of MAPK crosstalks need further exploration.
Methods
BCG
BCG vaccine Danish strain 1331 (Statens Serum Institut)
was used in all experiments. The vaccine has passed the
safety test, in which there are no macroscopic signs of
tuberculosis in vaccinated animals, as stated in the Certif-
icate of Analysis provided by Quality Assurance Depart-
ment, Statens Serum Institut, Copenhagen, Denmark.
Isolation of PBMo
PBMo were isolated from buffy coats of healthy blood
donors (source: the Hong Kong Red Cross Blood Transfu-
sion Service) by Ficoll-Paque (Pharmacia Biotech) density
gradient centrifugation as before [17-19] with modifica-
tion using MACS® Technology according to the manufac-
turer's instructions (Miltenyi Biotec, Germany). Approval
has been obtained from Hong Kong Red Cross Blood
Transfusion Service for the use of donors' blood. Institu-
tional Review Board of the University of Hong Kong has
given exemption to this project since it did not involve the
use of human or animal subjects. Briefly, the fresh leuko-
cytes were centrifuged at 3000 r.p.m. for 15 minutes and
were separated into plasma and cell layers. Plasma was
removed and incubated at 56°C for 30 minutes. It was
quickly chilled on ice and centrifuged at 3000 r.p.m. for
10 minutes. The supernatant was then filtered through
syringe filter and used as the autologous plasma. The cell
layer was diluted with PBS in the ratio of 1:1. The diluted
cells were overlaid over the Ficoll very slowly and centri-
fuged at 2300 r.p.m. for 20 minutes. The lymphocyte/
monocyte layer was removed and washed with RPMI
medium 1640 until the supernatant was clear. The cell
pellet was resuspended in PBS with CD14 MicroBeads
(Miltenyi Biotec, Germany) and incubated at 4°C for 30
minutes. The cells were washed with PBS and passed
through MACS® LS Columns placed in a MACS® Separator.
The columns were washed with PBS for three times and
were removed from the separator. PBMo were flushed out
from the columns by applying the plunger. The cells were
finally seeded onto the tissue culture plates in RPMI, sup-
plemented with 5% autologous plasma. Cell purity of
CD14+ monocytes, measured by flow cytometry and anti-
body conjugated with PE against CD14 (Beckman,
France), was >90%.
Isolation of RNA
Total RNA extraction was done by using TRIzol reagent
(Invitrogen, USA) according to the manufacturer's
instructions. Cells were lysed in TRIzol reagent at room
temperature for 5 minutes to allow for complete dissocia-
tion of nucleoprotein. Chloroform was then added. The
tube was vigorously shaken for 15 seconds and incubated
at room temperature for 3 minutes. The sample was cen-
trifuged at 4°C for 15 minutes at 13,200 r.p.m. The color-
less upper aqueous phase was transferred to a fresh tube.
RNA was precipitated from aqueous phase by mixing with
one volume of isopropyl alcohol at room temperature for
10 minutes. The sample was centrifuged again at 4°C for
10 minutes at 13,200 r.p.m. The supernatant was removed
and the RNA pellet on the side and bottom of the tube was
washed once with 75% ethanol. The sample was mixed by
vortexing and centrifuged at 4°C for 5 minutes at 13,200
r.p.m. After removing the ethanol, the RNA pellet was
dried in air for 10 minutes. Each RNA sample was dis-
solved in DEPC-water mixed with RNase inhibitor (Amer-
sham Biosciences, USA). It was finally mixed with DNase
buffer [25 mM Tris-HCl (pH 7.4), 5 mM MgCl2], 1 unit of
DNase at 37°C for 15 minutes and then at 70°C for 10
minutes for deactivating the DNase. The samples were
stored at -70°C until use.
Reverse Transcription - Polymerase Chain Reaction (RT-
PCR)
First-strand cDNA was reverse-transcribed in a 20 μl reac-
tion. DNase-treated RNA and 0.5 μg oligo(dT) primer
(Invitrogen, USA) were heated at 70°C for 10 minutes
and chilled quickly on ice. The product was then mixed
with first strand buffer (50 mM Tris-HCl [pH 8.3], 75 mM
KCl, 3 mM MgCl2), 10 mM dithiothreitol (DTT), 0.5 mM
deoxyribonucleoside triphosphates (dATP, dTTP, dCTP
and dGTP) and 100 units of SuperScript™ II Reverse Tran-
scriptase (Invitrogen, USA) at 42°C for 1 hour. The prod-
uct was stored at -20°C until use for PCR and QPCR
assays. Amplification of the reverse-transcribed cDNA was
performed in a 25 μl reaction. PCR assays contained 5BMC Immunology 2009, 10:64 http://www.biomedcentral.com/1471-2172/10/64
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pmol of each upstream and downstream primer, 1 unit of
Taq DNA polymerase (Amersham Biosciences, USA), 0.2
mM each dNTP, and PCR reaction buffer [50 mM KCl, 1.5
mM MgCl2, and 10 mM Tris-HCl (pH 9.0)]. PCR were
allowed to proceed for various cycles (94°C for 30 s, melt-
ing temperature (TM) for 30 s, and 72°C for 1 min). PCR
primer sets used and assay conditions were as follows: (1)
GAPDH, 25 cycles (TM = 60°C), upstream, 5'-
ACCACAGTCCATGCCATCAC-3', downstream, 5'-
TCCACCACCCTGTTGCTGTA-3'; (2) MKP-1, 35 cycles
(TM = 52°C), upstream, 5'-GCTGTGCAG-
CAAACAGTCGA-3'; downstream, 5'-CGATTAGTCCT-
CATAAGGTA-3' and (3) TNF-α, 30 cycles (TM = 56°C),
upstream, 5'-GGCTCCAGGCGGTGCTTGTTC-3', down-
stream, 5'-AGACGGCGATGCGGCTGATG-3'. PCR prod-
ucts were analyzed on a 1% agarose gel with ethidium
bromide and visualized under ultraviolet light. In order to
check the size of the PCR products, 1 kb Plus DNA Lad-
der™ (Invitrogen, USA) was run along with the PCR prod-
ucts.
Quantitative polymerase chain reaction (QPCR)
To perform QPCR, the levels of MKP-1, and TNF-α mRNA
as well as the reference gene GAPDH (as internal control)
were assayed by the gene-specific Assays-on-Demand rea-
gent kits (Applied Biosystems, USA). All samples were run
in duplicates or triplicates and with no template controls
on an ABI Prism 7700 Sequence Detector. The analysis
method of QPCR was the comparative cycle number to
threshold (CT) method as described in user bulletin no. 2
of the ABI Prism 7700 Sequence Detection System. The
number of CT of the targeted genes was normalized to that
of GAPDH in each sample (ΔCT). The CT value of the
treated cells was compared with that of the untreated or
mock-treated cells (ΔΔCT). The relative gene expression of
the targeted genes (fold induction) was calculated as 2-
ΔΔCT.
Protein extraction
Total cellular proteins were extracted by lysing cells in
lysis buffer containing 1% Triton X-100, 0.5% NP-40, 150
mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM
EGTA (pH 8.0), 1% SDS, 0.2 mg/ml PMSF, 1 μg/ml apro-
tinin, 1 mM sodium orthovanadate, 2 μg/ml pepstatin, 2
μg/ml leupeptin, and 50 mM sodium fluoride for 5 min-
utes. The homogenate was then boiled for 10 minutes and
stored at -70°C until use. The concentrations of total pro-
tein in cell extracts were determined by BCA™ Protein
Assay Kit (Pierce, IL, USA).
Western blot analysis
Western blot was done as described [20]. Equal amounts
of protein were separated by 10% SDS-PAGE, electroblot-
ted onto nitrocellulose membranes (Schleicher &
Schuell), and followed by probing with specific antibod-
ies for Actin, MKP-1 (Santa Cruz Biotech., USA), phos-
pho-p38 MAPK, phospho-ERK1/2 (Cell Signaling, USA).
After three washes, the membranes were incubated with
the corresponding secondary antibodies. The bands were
detected using the Enhanced Chemiluminescence System
(Amersham Pharmacia Biotech) as per the manufacturer's
instructions.
Transfection of siRNA
Transfection of siRNA into human monocytes was done
as described [21]. MKP-1 siRNA included (i) MKP1-
HSS102982, AAACGCUUCGUAUCCUCCUUUGAGG;
(ii) MKP1-HSS102983, UUAUGCCCAAGGCAUCCAG-
CAUGUC; and (iii) MKP1-HSS102984, UGAUG-
GAGUCUAUGAAGUCAAUGGC. MKP-1 knockdown in
PBMo was conducted by using MKP1-HSS102983 only or
a pool of the above three different MKP-1 Stealth™ Select
RNAi (ratio = 1:1:1, 200 nM, Invitrogen, USA). Stealth™
RNAi Negative Control Duplex (200 nM) was used as a
control for sequence independent effects for the siRNA
transfection. Transfection of monocytes was done by
using jetPEI™ DNA transfection reagent (Polyplus Trans-
fection, USA) according to the manufacturer's instruc-
tions. After transfecting the cells for 24 h, the transfectants
were treated with different inducers as described above.
Statistical Method
Statistical analysis was performed by Student's t test. Dif-
ferences were considered statistically significant when p
values were less than 0.05.
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